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Treatment of primary carcinoma of the liver constitutes a challenge to the physi-
cian, and despite aggressive treatment, the prognosis is poor. The resection rate for 
primary liver maJignancy ranges from 15 to 30% in several studies. Although there 
has been an increase in the resection rate because of improvements in surgical 
techniques and postoperative care, the overall prognosis remains grim [111. It was 
in the presence of such discouraging facts that liver transplantation was undertaken 
as the only hope in patients with unresectable lesions. 
The experience with orthotopic liver transplantation in 55 patients with primary 
hepatic malignancy is the basis of this chapter. An update will be provided of are· 
cent report on the same subject [7]. 
I. CLINICAL FEATURES 
From March 1, 1963, to August 1,1985,575 patients received orthotopic liver 
transplantations for several hepatic diseases. Treatment was performed at the Uni-
versity of Colorado Health Sciences Center until the end of 1980, and during that 
period of time, the immunosuppression mostly consisted of azathioprine, anti-
lymphocyte globutin (ALG), and steroids. Since 1981, treatment has been pro-
vided at the University of Pittsburgh Health Center and the immunosuppression 
has consisted of cyc1osporine and steroids. 
Supported by Research Grants from the Veterans Administration and Project Grant No. AM· 
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Table 1 Number of Patients Receiving Orthotopic Uver Trans-
plantation in the Presence of Primary Hepatic Malignancy 
Total no. No. patients with 
Year transplants primary malignancy % 
1963 5 4 80 
1966 100 
1967 6 1 16.6 
1968 12 4 33.3 
1969 6 2 33.3 
1970 10 10 
1971 II 1 9.1 
1972 11 0 
1973 13 0 
1974 20 4 20 
1975 9 11.1 
1976 14 2 14.3 
1977 21 4.8 
1978 19 5.3 
1979 12 8.3 
1980 14 2 14.3 
1981 26 5 19.2 
1982 62 6 9.7 
1983 76 8 10.5 
1984 135 10 7.4 
1985 132a 0.8 
aUntn August I, 1985. 
A total of 55 patients (9.6%) received orthotopic liver transplants in the presence 
of primary hepatic malignancy, with the annual distribution shown in Table 1. 
There were 32 females and 23 males, and their ages ranged from 2 to 68 years, 
with a mean of 30. Table 2 lists the histological types of primary liver cancer found 
in this series. The most common malignancy encountered was hepatocellular car-
cinoma, which was present in 38 patients (69%); 7 of the 38 had the fibrolamellar 
variant. The other tumors were 8 bile duct carcinomas (Klatskin tumors), 3 epith-
eloid hemangioendothelial sarcomas, 2 cholangiocarcinomas, and 1 each hepato-
blastoma, angiosarcoma, adenocarcinoma of unknown primary, and sarcoma of 
undetennined cell type. 
\ 
I 
I 
I 
I 
I 
, 
I 
, 
\ 
I 
. 
\ 
\ 
!K:KKI;K;--~-:I 
K~ ... ~ ....... -
.' -
- , 
_::-
I 
t ; 
Transplantation for Primary Liver Cancer 479 
Table 2 Histological Diagnosis of Primary Liver Cancers in Patients Treated with 
Orthotopic Liver Transplants 
Diagnosis Male Female Total (%) 
Hepatocellular carcinoma 16 22 38 (69) 
Bile duct carcinoma (Klatskin tumor) 5 3 8 (14.5) 
Epitheloid hemangioendothelial sarcoma 0 3 3 (5.5) 
Cholangiocarcinoma 1 2 (3.6) 
Hepatoblastoma 0 1 (1.8) 
Hemangiosarco rna 0 I (1.8) 
Sarcoma (unclassified) 0 1 (1.8) 
Adenocarcinoma (unknown primary) 0 1 (l.8) 
A total of 42 patients (76%) were known to have unresectable lesions and reo 
ceived liver transplants as the principal method of therapy. For didactic purposes, 
this group of patients will be referred to as "unresectable malignancy." The first 
20 patients were treated with azathioprine, prednisone, and anti·lymphocyte 
globulin; the rest were treated with cyclosporine and prednisone. 
A total of 13 patients (24%) received transplants for nonneoplastic end·stage 
liver disease and were found to have coincidental primary liver malignancy. This 
group will be referred to as "incidental malignancy." Of these patients, 3 were 
treated with azathioprine, prednisone, and ALG, and 10 were treated with cyclo· 
sporine and prednisone. 
II. UNRESECT ABLE MALIGNANCY 
Preoperative evaluation for extrahepatic involvement was negative in this group of 
patients; however, 3 patients had metastatic disease at the time of transplantation 
and were left with gross residual neoplasm. A 27·year·old n:tan with sarcoma of 
undetermined cell type was found to have fme metastatic lesions in the peritoneal 
cavity and lungs at the time of transplantation; nevertheless, this patients is still 
alive at this writing with no evidence of metastatic disease over a 9-year period. The 
second patient was a 35-year-old female who was found to have metastases to the 
lungs and peritoneum during the surgical intervention. This patient died 3 months 
later, and in addition, the autopsy revealed metastases to the bone marrow. The 
third patient was a 54-year-old female who was noted to have metastatic involve· 
ment in the regional lymph nodes. After some controversy, the tumor was classi-
fied as an adenocarcinoma of unknown primary. This patient, who received two 
courses of doxorubicin hydrochloride (adriamycin) and vincristine (Oncovin and 
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Table 3 Coexistent Liver Disease in Patients with Unresectable Primary Hepatic 
Malignancies 
Coexistent disease N = patients (%) Age (years) 
Immunosuppression with azathioprine + 
prednisone + ALG (N = 20) 
Postnecrotic cirrhosis 4 (20) 29,43,48,52 
Biliary atresia 1(5) 11 
Tyrosinemia 1 (5) 9 
Immunosuppression with cyclosporine + 
prednisone (N = 22) 
Postnecrotic cirrhosis 2 (9) 51,53 
Sclerosing cholangitis 1 (4.5) 33 
Thorotrast liver 1 (4.5) 52 
Tyrosinemia 1 (4.5) 5 
a course of 5-fluorouracil, cyclosphosphamide (Cytoxan) and methotrexate pre-
operatively, is alive with no evidence of tumor spread over a lO-month period. 
A total of 6 patients during the azathioprine and 1 during the cyc1osporine pe-
riods died of various complications of liver transplantation within 1 month of the 
operation. A single patient had evidence of extrahepatic tumor involvement at the 
autopsy. This patient was a 52-year-old male with a cholangiocarcinoma who died 
on postoperative day 5 of graft failure, sepsis, and pulmonary embolism. The post-
mortem examination revealed metastases to the bone, lungs, kidney, and lymph 
nodes. 
A list of coexistent liver diseases in some of these patients is given in Table 3, 
but they had no effect in the fmal outcome. 
A. Azathioprine Era 
1. Recurrence 
Omitting 6 patients who died postoperatively, 14 patients survived at least 2 
months and thus became available for meaningful observation about recurrence 
(Table 4). 
The recurrence rate was 64%. In patients with hepatocellular carcinoma, in-
cluding the patient with the fibrolamellar tumor, the recurrence rate was 66%. 
The malignancy recurred from 2 to 13 months, with a mean of 4 months. The pa-
tient with the fibrolamellar variant had the longest tumor-free interval, which was 
13 months. All these patients died of carcinomatosis, and the most common or-
gans involved were the allograft and lungs. 
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Table 4 Liver Transplantation in Patients with Unresectable Primary Liver Car-
cinoma During Azathioprine + Prednisone Period 
Recurrence No. survivors 
Histology No. patients (%) (%) 
Hepatocellular carcinoma 8 5 (62.5) 0(0) 
Fibrolamellar variant 1 (100) 
Bile duct cancer (Klatskin tumor) 3 2 (66) 0(0) 
Epitheioid hemangioendothelial 
sarcoma 1 (100) 0(0) 
Sarcoma of undetermined cell type l a 0(0) 1 (l00) 
apatient had intra-abdominal and pulmonary metastases at transplantation. 
Of 3 patients with bile duct carcinoma, 2 had recurrence at 21 and 42 months, 
respectively_ The organs involved were the allograft and bile duct and were the cause 
of the patients' demise. 
2 Survival 
There has been only 1 survivor in the azathioprine group. This patient, previously 
mentioned, had a sarcoma of undetermined cell type with metastases at the time 
of transplantation; however, he is alive and free of disease 9 years later. A total of 
9 patients (64%) died of recurrent disease. The remaining 4 patients died of various 
infections at 2, 2, 3, and 6 months, respectively. The postmortem examinations 
revealed no residual tumor. Of the 20 patients, 35% survived 6 months and 3cm 
survived 1 year, of whom all but 1 subsequently died. 
8. Cyclosporine Era 
1. Recurrence 
In the cyclosporine era, only 1 patient died within 1 month ofthe operation of 
sepsis and graft failure. The autopsy disclosed no residual neoplasm. 
\ 
\ 
\ 
\ 
The recurrence rate according to the type of malignancy in the remaining 21 
patients is shown in Table 5. The recurrence rate was 58%, excluding the 2 pa· 
tients who were left with gross tumor at the time of the operation. The incidence 
of recurrence was 50% in patients with hepatocellular carcinoma and 50% in pa-
tients with the fibrolamellar variant. All non-fibrolamellar hepatocellular carcino-
mas recurred within 1 year, from 4 to 12 months with a mean of 6 months, whereas 
the fibrolamellar type recurred after 1 year, from 13 to 30 months with a mean of 
20 months. The 2 patients with bile duct carcinoma (Klatskin tumor) and another 
patient with cholangiocarcinoma had recurrent disease at 6,10, and IS months, 
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Table 5 Liver Transplantation in Patients with Unresectable Primary Liver Car-
cinoma During Cyclosporine and Prednisone Period 
Recurrence No. survivors 
Histology No. patients (%) (%) 
Hepatocellular carcinoma 8 4 (50) 3(37.5)3 
Fibrolamellar 6 3 (50) 4 (66)b 
Bile duct carcinoma 2 2 0(0) 
Cholangiocarcinoma 1 1 0(0) 
Epitheloid hemangiosarcoma 2 1 (50) 1 (50) 
aOne patient had metastatic disease. 
bTwo patients have metastatic disease. 
respectively. The most common organs involved were the liver and lungs. Occasional 
metastases to bone and brain were also observed. 
2. Survival 
The 6-month actuarial survival is 82%, reflecting the much improved recovery with 
cyclosporine therapy [15] ; however, there is a decline in survival thereafter, chiefly 
from recurrence of malignancy, as shown in Table 5. At this writing, there are only 
9 patients alive of the origina122 (41 %) from 4 months to 48 months with a mean 
of approximately 23 months, but 1 of these survivors is a patient who had involve· 
ment of regional lymph nodes, and there are 3 others with known recurrences of 
hepatocellular carcinoma. Of the 14 patients with hepatocellular carcinoma, in· 
cluding the fibrolamellar variant, 4 are tumor free from 4 months to 4 years. In 
this particular group, the 2 longest survivors (27 and 48 months) had fibrolamellar 
hepatocellular carcinoma. 
Death in patients with recurrent disease was directly related to the presence of 
malignancy. The causes of death in 4 other patients who died at 1,2,2, and 13 
months wae graft failure, ischemic necrosis of the colon. Candida sepsis, and liver 
dysfunction following retransplantation, respectively. .. . . 
III. INCIDENTAL MALIGNANCY 
There are 13 patients who received liver transplants for end·stage non·neoplastic 
liver disease and whose livers were found to contain incidental primary malignan. 
cies (Table 6). Ages ranged from 2 to 52 years with a mean of 16 years. Tumors 
could have been totally removed by partial hepatectomy if the liver had not been 
so seriously diseased. Of the 3 patients who belong to the azathioprine period, 1 
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Table 6 Liver Transplantation in Patients with Incidental Primary Liver Car-
cinoma 
Recurrence No. survivors 
Histology No. patients (%) (%) 
Hepatocellular carcinoma 11 0(0) 11 (100) 
Hepatoblastoma 0(0) 1 (100) 
died on the ftrst postoperative day. Hepatocellular carcinoma was found in 12 
patients and a hepatoblastoma in 1 patient. Of the 13 patients, 12 are alive and 
free of recurrence (Table 6) from 10 months to more than 15 years. Table 7 lists 
the liver diseases for which liver transplantation was performed. 
IV. GENERAL COMMENTS AND CONCLUSIONS 
Primary hepatic malignancy, particularly hepatocellular carcinoma, carries a bleak 
prognosis. Many patients were diagnosed when the extension of the disease was 
such that treatment by conventional partial hepatectomy was not possible, lead· 
ing to the early trials in liver transplantation [3,8,13,14]. The interest for this type 
of therapy persists because an effective alternative method of treatment is lacking 
and because the overall survival rate has improved in recent years with the intro-
duction of cyclosporine and new surgical techniques [15]. 
The overall recurrence rate was high since almost two-thirds of the patients with 
umesectable lesions and who survived at least 2 months developed metastatic dis-
ease. Hepatocellular carcinoma is one of the most malignant neoplasms in terms of 
prognosis as became evident in this series, in which a 57% recurrent rate was ob-
served. The nonftbrolamellar hepatocellular carcinoma recurred within 1 year of 
the operation, leading to a prompt death of the patients. Several factors may be 
Table 7 Coexistent Disease in Patients with Incidental Primary 
Liver Carcinoma 
Disease No. patients Age (years) 
Biliary atresia 3 3,7,8 
Tyrosinemia 4 2,3,3,21 
a1-Antitrypsin deficiency 2 5,47 
Alagille's syndrome 9 
Alcoholic cirrhosis 1 52 
Cirrhosis, HBsAg-positive 1 45 
Sea-blue histiocyte syndrome 7 
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implicated in this high recurrence rate. First, the extent of the disease may be too 
advanced by the time the patients received the transplants. Second, hepatocellular 
carcinoma is an aggressive cancer that invades vascular structures early [11]. Tu-
mor thrombi in the portal vein and its branches are not an unusual occurrence in 
advanced hepatocellular carcinomas. In a series of 232 cases in Japan, Nakashima 
et a1. reported portal vein invasion in 64.7% and in the major hepatic veins in 23.2%. 
Moreover, extrahepatic metastases may be spread via blood vessels or lymphatics 
or by continuity in the abdominal cavity [10]. Third, immunosuppression may 
enhance the growth of residual nest cells, as was suggested years ago [141 and sup-
ported recently in several investigations [1,6,9]. 
The fibrolamellar hepatic carcinoma is an exception. This tumor, which was or-
iginally described by Edmunson [5] and Peters [12] ,is known to be less aggressive 
than other primary hepatic carcinomas [2,4,16]. Although the recurrence rate was 
similar to that of the common hepatocellular carcinoma, the metastases appeared 
later and grew relatively slowly. In fact, one of the patients is still alive and well 2 
years after the development of pulmonary metastases. Because of these character-
istics, patients with this particular tumor appear to benefit from liver transplanta-
tion. 
The prognosis with bile duct carcinoma (Klatskin tumor), cholangiocarcinoma, 
and sarcoma was very poor_ Nonetheless, an occasional patient has had complete 
arrest and control of the malignant process. These results suggest that liver trans-
plantation alone is not sufficient to control primary liver cancer, perhaps with the 
exception of the fibrolamellar carcinoma. However, chemotherapy may not be 
effective enough, since recently 2 patients who had nonfibrolamellar hepatocellu-
lar carcinoma and received aggressive treatment with adriamycin and other chemo-
therapeutic agents developed metastases within a few months; nevertheless, con-
trolled prospective studies are certainly in order • 
The striking aspect of this experience was the absence of recurrence in patients 
who were found to have an incidental primary hepatic carcinoma; therefore, the 
presence of hepatic malignancy appears not to be an absolute contraindication to 
liver transplantation. 
V. SUMMARY 
Orthotopic liver transplantation in patients with primary liver malignancy is re-
viewed. The recurrence rate was high in patients with unresectable cancer regard-
less of the histological diagnosis, leading to a prompt death of the patients. The 
only exception is the fibrolamellar variant of hepatocellular carcinoma in which, 
despite a recurrent rate of 57%, the metastases occurred late and grew slowly. Of 
the 42 patients with unresectable malignancy, only 10 patients are alive; however, 
1 patient was left with residual cancer involving the regional lymph nodes and 3 
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others have metastases. Therefore, only 6 (14%) are possibly free of malignancy 
from 4 mon ths to 9 years. 
The encouraging aspect of this experience is that patients who had liver replace-
ments for nonneoplastic end-stage liver disease and were found to have incidental 
malignancy have had no recurrence; therefore, the mere presence of a primary liver 
carcinoma is not an absolute contraindication for liver transplantation. 
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